Prospective surveillance vs clinically driven approach for CMV reactivation after autologous stem cell transplant
- 1 February 2016
- journal article
- Published by Elsevier in Journal of Infection
- Vol. 72 (2) , 265-268
Abstract
No abstract availableThis publication has 9 references indexed in Scilit:
- Cytomegalovirus reactivation after autologous stem cell transplantation in myeloma and lymphoma patients: A single-center studyWorld Journal of Transplantation, 2015
- Clinical impact of neutropenia related with the preemptive therapy of CMV infection in solid organ transplant recipientsJournal of Infection, 2014
- High incidence of post‐transplant cytomegalovirus reactivations in myeloma patients undergoing autologous stem cell transplantation after treatment with bortezomib‐based regimens: a survey from the Rome Transplant NetworkTransplant Infectious Disease, 2013
- The potential role of pre‐transplant HBcIgG seroposivity as predictor of clinically relevant cytomegalovirus infection in patients with lymphoma undergoing autologous hematopoietic stem cell transplantation: A study from the Rome Transplant NetworkAmerican Journal of Hematology, 2011
- Infections in Patients with Multiple Myeloma in the Era of High‐Dose Therapy and Novel AgentsClinical Infectious Diseases, 2009
- How we treat cytomegalovirus in hematopoietic cell transplant recipientsBlood, 2009
- Management of CMV, HHV-6, HHV-7 and Kaposi-sarcoma herpesvirus (HHV-8) infections in patients with hematological malignancies and after SCTBone Marrow Transplantation, 2008
- Cytomegalovirus infection after autologous stem cell transplantation: incidence and outcome in a group of patients undergoing a surveillance programTransplant Infectious Disease, 2005
- Cytomegalovirus infection and non‐neutropenic fever after autologous stem cell transplantation: high rates of reactivation in patients with multiple myeloma and lymphomaBritish Journal of Haematology, 2001